CSI Market
Sign In | Register

Scinai Immunotherapeutics Ltd (SCNI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SCNI Annual Cash Flow →
Quarterly cash flow trends provide additional context on Scinai Immunotherapeutics Ltd's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2023)
Operating Activities
Income-8.31
Depreciation & amortization1.42
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.30
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Adjustments For Decrease Increase In Trade And Other Receivables-
Increase Decrease In Trade Payables And Other Accounts Payables-
Increase In Short And Long Term Other Payables-
Total Changes In Asset And Liability-
Expense Of Inprocess Research And Development-
Financial Income Related To Loan From Others-
Operating Lease Right Of Use Asset Amortization Expense-
Debt Related Commitment Fees And Debt Issuance Costs-
Financial Expense Related To Loan From Others-
Gains Losses On Restructuring Of Debt-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-0.04
Accounts Payable0.03
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-0.09
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.15
Discontinued operations0.00
Net Cash flow from Operating Activities-6.03
Investing Activities
Capital Expenditures0.02
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceed From Sale Of Property Plant And Equipment-
Decrease Increase In Other Longterm Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.02
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.06
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Increase Decrease In Cash And Cash Equivalents-
Proceeds From Issuance Of Options To Public-
Issuance Of Warrants-
Proceeds From Issuance Of Ordinary Shares For S E P A Holders Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.77
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-6.01
Total Cash Flow-0.28
4 historic quarters locked

Sign in to unlock the full Scinai Immunotherapeutics Ltd cash flow history.

Sign In Create Free Account

About Scinai Immunotherapeutics Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-038011

Figures are derived from filed reports and may be restated. Historical data is subject to revision.